OncoLens
Highly Engaged Employees
Highly Engaged EmployeesHealthcare Software · Georgia, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
75 5th St NW, Atlanta, Georgia, 30308, U...Website
www.oncolens.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
1
About OncoLens
OncoLens is an AI-enabled digital healthcare platform that provides a comprehensive multidisciplinary care solution for oncology. The platform is utilized by over 10% of cancer centers and 50% of top pharmaceutical companies in the U.S. to enhance patient outcomes through coordinated data analysis and clinical decision support. With a network of more than 5 million oncology patients and 45,000 multidisciplinary physicians, OncoLens streamlines workflows and improves trial matching and biomarker testing. Their services cater to both healthcare providers and life sciences organizations, driving innovation and precision in cancer care.Explore more
OncoLens Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is OncoLens your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at OncoLens
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if OncoLens has recently received funding, and reach out quickly before it becomes old news!
OncoLens, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on OncoLens recently announced quarterly report
Product Launch: Get notified when OncoLens launches new products
Check out if OncoLens is spiking on competitors!
Click to see if OncoLens had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once OncoLens has new funding data
Recommended Actions
Find VP level buyers at OncoLens
Find 3 more new buyers
Compare Similar Companies to OncoLens
Compare insights from companies similar to OncoLens, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
OncoLens is experiencing very low activity levels compared to other companies in the Software sector.
What does this means?
OncoLens is drawing exceptional interest within the Software industry, suggesting notable developments or strong market momentum, learn more about OncoLens.
OncoLens financials insights
Gather financial insights about OncoLens, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Angel/Seed
$1.4M
2020
Private Equity
$2.5M
2021
Series A
$7.3M
2024
Series B
$16M
OncoLens Tech Stack
A closer look at the technologies used by OncoLens
See more technologies
Most Recent Scoops
Award
Award, Finance
Open Position
Event
Product Marketing, Events, Training, Medical Research, Field /Outside Sales, Clinical Operations, Field Marketing, Healthcare Technology
Event
Product Marketing, Events, Software, Field /Outside Sales, Field Marketing, Healthcare Operations, Healthcare Technology
Open Position
Top Healthcare Software Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding OncoLens
Sign Up For FreeTo access detailed company insights
OncoLens is an AI-enabled digital healthcare platform that provides a comprehensive multidisciplinary care solution for oncology. The platform is utilized by over 10% of cancer centers and 50% of top pharmaceutical companies in the U.S. to enhance patient outcomes through coordinated data analysis and clinical decision support. With a network of mo... Read More
